Figure 2.
ERKi has a synergistic anti-cancer effect with rapamycin. (A) A549, PC9 and H1650 cells were treated with increasing concentrations of rapamycin alone, or 25, 50 nM trametinib, or in combination for 48h, and cell viability was measured by CCK8 assay. (B) CCK8 data were analyzed by CompuSyn software to calculate CI between trametinib and rapamycin at different concentrations in A549, PC9 and H1650 cells, and Fa-CI plot was shown.